Clinical trials: Shingles, open to volunteers
Zoster; Herpes
Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation
Shingles is caused by the same virus that causes chickenpox. After someone has chickenpox, the virus stays in the body and can become active again later in life. This is called shingles.
- Trial name
- ZEST (NCT07443709)
- Testing
- Booster dose of the recombinant zoster vaccine (RZV, Shingrix®)
- Where
- Switzerland
- Volunteers
- 75 people
- Sponsor
- Oriol Manuel
Herpes Zoster Pain
The Efficacy of High-frequency Short-time Spinal Cord Stimulation in the Treatment of Herpes Zoster-associated Neuralgia
Zoster-associated neuralgia (ZAN) is a type of neuropathic pain caused by the reactivation of the varicella-zoster virus (VZV). The global annual incidence is approximately 3-5 per 1,000 individuals, and in China, the incidence…
- Trial name
- NCT06942806
- Testing
- HF-SCS parameter settings: Frequency 1000 Hz, pulse width 60-180 μs, amplitude 0.5-3.0 V, LH-SCS parameter settings: Frequency 30-100 Hz, pulse width 100-300 μs, amplitude 0.5-5.0 V
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Li Zhao
Herpse Zoster
A Study on the Live-Attenuated Herpes Zoster Vaccine for Sequential Booster Immunization Following Recombinant Herpes Zoster Vaccine
Evaluate the immunogenicity after boost vaccination with the live attenuated herpes zoster vaccine.
- Trial name
- NCT07753265
- Testing
- live-attenuated zoster vaccine
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Herpes Zoster
A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
The study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of 3 dose levels of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50…
- Trial name
- NCT07205796
- Testing
- HZ Vaccine (IN001), Shingrix
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd
Herpes Zoster (HZ)
Multimodal Nerve Block and Pulse Radiofrequency for Acute Herpes Zoster Pain
The primary objective of this clinical trial is to evaluate the efficacy of liposomal bupivacaine and ropivacaine in the treatment of pain associated with herpes zoster (shingles).
- Trial name
- NCT06798662
- Testing
- Ultrasound-Guided Pulsed Radiofrequency (PRF), Intercostal nerve block (2% ropivacaine or 133 mg of liposomal bupivacaine), Paravertebral (PVB) Block (2% ropivacaine or 133 mg of liposomal bupivacaine)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xiaguang Duan
Herpes Zoster (HZ)
A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals
The purpose of this clinical study is to evaluate the safety and immunogenicity of receiving two doses of recombinant herpes zoster vaccine (CHO cells) (RHZV) in healthy individuals aged 40 years and above.
- Trial name
- NCT06932523
- Testing
- Recombinant herpes zoster vaccine with low-dose adjuvant, Recombinant herpes zoster vaccine with high-dose adjuvant, Low-dose adjuvant
- Where
- China
- Volunteers
- 645 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Vaccine-Preventable Diseases, Herpes Zoster
A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine
This clinical trial is to study protective efficacy and safety of a recombinant herpes zoster vaccine (LZ901) and sponsored by Beijing Luzhu Biotechnology Co., Ltd.
- Trial name
- NCT06088745
- Testing
- Recombinant Herpes Zoster Vaccine
- Where
- China
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Beijing Luzhu Biotechnology Co., Ltd.
Varicella-zoster Virus
Phase III Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above
The primary objective of this study is to evaluate the vaccine efficacy, safety and immunogenicity of 2 injections (approximately 2 months apart) of ABO1108 in adults aged 40 years or above.
- Trial name
- NCT07817108
- Testing
- ABO1108
- Where
- 4 sites in China
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
Herpes
A Phase I Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell)
To evaluate the safety and tolerability of different dosages of recombinant zoster vaccine (CHO cell) when administered to adults aged 40 years and older.
- Trial name
- NCT07633197
- Testing
- Recombinant Herpes Zoster Vaccine
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Post Herpetic Neuralgia (PHN)
Transcutaneous Auricular Vagus Nerve Stimulation on Post-Herpetic Neuralgia
The purpose of this study is to evaluate the therapeutic efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) in the treatment of patients with post-herpetic neuralgia (PHN).
- Trial name
- NCT07123987
- Testing
- transcutaneous auricular vagus nerve stimulation (taVNS), traditional medical treatment for PHN
- Where
- Egypt
- Volunteers
- 34 people
- Sponsor
- Mohamed Hosny Ismail Easa
Varicella (Chickenpox)
SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years
The goal of this study is to evaluate the safety and immunogenicity of an investigational varicella vaccine in children. Researchers will compare the investigational vaccine, NBP608, with licensed varicella vaccines.
- Trial name
- NCT07415252
- Testing
- NBP608 (Mid Potency), NBP608 (Low Potency), Varivax®
- Where
- 14 sites in Honduras, Philippines and 2 more
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
Type 1 Diabetes Mellitus
SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.
Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by progressive destruction of pancreatic beta cells mediated by autoreactive T lymphocytes, resulting in absolute insulin deficiency.
- Trial name
- SHIELD-T1D (NCT07614412)
- Testing
- Recombinant Zoster Vaccine (Shingrix; RZV), Semaglutide (Ozempic®)
- Where
- Saudi Arabia
- Volunteers
- 240 people
- Sponsor
- Ministry of Health, Saudi Arabia
Immunocompromised Patients
Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail Patients
Herpes zoster (HZ) is a serious health problem whose incidence and severity increase with the decline of cell-mediated immunity (CMI) because of age and immunocompromised (IC) status.
- Trial name
- AID4FRAIL_RZV (NCT07321808)
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Herpes Zoster, Pain
The Analgesic Efficacy and Safety of Flurbiprofen Patch in Patients With Herpes Zoster
Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia.
- Trial name
- NCT07370402
- Testing
- Flurbiprofen patch combined with conventional therapy group, Conventional therapy group
- Where
- China
- Volunteers
- 750 people
- Sponsor
- Beijing Tiantan Hospital
Herpes Zoster
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine
The purposes of the study are to evaluate the Safety, Tolerability, and Immunogenicity of different dose levels of recombinant herpes zoster vaccine with 2 doses 60 days apart in healthy subjects aged 40 years and older.
- Trial name
- NCT06801509
- Testing
- Recombinant Herpes Zoster Vaccine (SCTV04C) Low-Dose, Recombinant Herpes Zoster Vaccine (SCTV04C) High-Dose, Shingrix®
- Where
- China
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Herpes Zoster, Pain
The Analgesic Efficacy and Safety of Crisugabalin in Patients With Herpes Zoster
Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia.
- Trial name
- NCT07307976
- Testing
- Crisugabalin combined conventional therapy, Conventional therapy
- Where
- China
- Volunteers
- 750 people
- Sponsor
- Beijing Tiantan Hospital
Herpes Zoster
Risk Factors of Anxiety and Depression in Patients With Herpes Zoster Neuralgia
The goal of this observational study is to explore risk factors of anxiety and depression in patients with herpes zoster neuralgia, and the changes of certain serum biomarkers and functional brain magnetic resonance images of…
- Trial name
- NCT06449547
- Testing
- Hospital Anxiety and Depression Scale
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Huazhong University of Science and Technology
Shingles
Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
This is a phase II study that will examine the immunogenicity of the Shingrix vaccine in patients following an allogeneic stem cell transplant.
- Trial name
- NCT05554068
- Testing
- Shingrix
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Loyola University
Bell's Palsy, Ramsay Hunt Syndrome
Safety and Effectiveness of the BlinkER System in Participants With Facial Nerve Palsy
Prospective, single-arm, multicenter, single-masked, pivotal study to Evaluate the Safety and Effectiveness of the Blinker system in Participants with Facial Nerve Palsy.
- Conditions
- Bell's Palsy, Ramsay Hunt Syndrome, Lyme Disease, Facial Palsy
- Trial name
- Paralysis (NCT06542289)
- Testing
- BlinkER device.
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Neurotrigger Ltd
Varicella
Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination
Primary objective is to assess the safety of MG1111 until Day 42 using as 2nd vaccination Secondary objective to assess the immunogenicity and safety of MG1111 using as 2nd vaccination
- Trial name
- NCT05422508
- Testing
- MG1111 (BARICELA), VARIVAX, Suduvax
- Where
- South Korea
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation